Literature DB >> 22593621

HLA-B27 homodimers and free H chains are stronger ligands for leukocyte Ig-like receptor B2 than classical HLA class I.

Joanna Giles1, Jackie Shaw, Christopher Piper, Isabel Wong-Baeza, Kirsty McHugh, Anna Ridley, Demin Li, Izabela Lenart, Antony N Antoniou, Katilin DiGleria, Kimiko Kuroki, Katsumi Maenaka, Paul Bowness, Simon Kollnberger.   

Abstract

Possession of HLA-B27 (B27) strongly predisposes to the development of spondyloarthritis. B27 forms classical heterotrimeric complexes with β(2)-microglobulin (β2m) and peptide and (β2m free) free H chain (FHC) forms including B27 dimers (termed B27(2)) at the cell surface. In this study, we characterize the interaction of HLA-B27 with LILR, leukocyte Ig-like receptor (LILR)B1 and LILRB2 immune receptors biophysically, biochemically, and by FACS staining. LILRB1 bound to B27 heterotrimers with a K(D) of 5.3 ± 1.5 μM but did not bind B27 FHC. LILRB2 bound to B27(2) and B27 FHC and B27 heterotrimers with K(D)s of 2.5, 2.6, and 22 ± 6 μM, respectively. Domain exchange experiments showed that B27(2) bound to the two membrane distal Ig-like domains of LILRB2. In FACS staining experiments, B27 dimer protein and tetramers stained LILRB2 transfectants five times more strongly than B27 heterotrimers. Moreover, LILRB2Fc bound to dimeric and other B27 FHC forms on B27-expressing cell lines more strongly than other HLA-class 1 FHCs. B27-transfected cells expressing B27 dimers and FHC inhibited IL-2 production by LILRB2-expressing reporter cells to a greater extent than control HLA class I transfectants. B27 heterotrimers complexed with the L6M variant of the GAG KK10 epitope bound with a similar affinity to complexes with the wild-type KK10 epitope (with K(D)s of 15.0 ± 0.8 and 16.0 ± 2.0 μM, respectively). Disulfide-dependent B27 H chain dimers and multimers are stronger ligands for LILRB2 than HLA class I heterotrimers and H chains. The stronger interaction of B27 dimers and FHC forms with LILRB2 compared with other HLA class I could play a role in spondyloarthritis pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593621      PMCID: PMC3622243          DOI: 10.4049/jimmunol.1102711

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  The ILT family of leukocyte receptors.

Authors:  D S Allan; A J McMichael; V M Braud
Journal:  Immunobiology       Date:  2000-05       Impact factor: 3.144

2.  Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor.

Authors:  Benjamin E Willcox; Leonard M Thomas; Pamela J Bjorkman
Journal:  Nat Immunol       Date:  2003-08-03       Impact factor: 25.606

3.  Cell-surface expression and immune receptor recognition of HLA-B27 homodimers.

Authors:  Simon Kollnberger; Lucy Bird; Mei-Yi Sun; Christelle Retiere; Veronique M Braud; Andrew McMichael; Paul Bowness
Journal:  Arthritis Rheum       Date:  2002-11

Review 4.  Leukocyte Ig-like receptor complex (LRC) in mice and men.

Authors:  Annalise M Martin; Jerzy K Kulski; Campbell Witt; Pierre Pontarotti; Frank T Christiansen
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

5.  Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling.

Authors:  Lucy A Bird; Chen Au Peh; Simon Kollnberger; Tim Elliott; Andrew J McMichael; Paul Bowness
Journal:  Eur J Immunol       Date:  2003-03       Impact factor: 5.532

6.  Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G.

Authors:  Mitsunori Shiroishi; Kouhei Tsumoto; Kimie Amano; Yasuo Shirakihara; Marco Colonna; Veronique M Braud; David S J Allan; Azure Makadzange; Sarah Rowland-Jones; Benjamin Willcox; E Yvonne Jones; P Anton van der Merwe; Izumi Kumagai; Katsumi Maenaka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

7.  HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors.

Authors:  Simon Kollnberger; Lucy A Bird; Matthew Roddis; Cecile Hacquard-Bouder; Hiromi Kubagawa; Helen C Bodmer; Maxime Breban; Andrew J McMichael; Paul Bowness
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

8.  High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells.

Authors:  John S Manavalan; Paola C Rossi; George Vlad; Flavia Piazza; Anna Yarilina; Raffaello Cortesini; Donna Mancini; Nicole Suciu-Foca
Journal:  Transpl Immunol       Date:  2003 Jul-Sep       Impact factor: 1.708

9.  HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses.

Authors:  Jinghe Huang; James J Goedert; Eric J Sundberg; Thai Duong Hong Cung; Patrick S Burke; Maureen P Martin; Liliana Preiss; Jeffrey Lifson; Mathias Lichterfeld; Mary Carrington; Xu G Yu
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307

10.  Crystal structure of LIR-2 (ILT4) at 1.8 A: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18.

Authors:  Benjamin E Willcox; Leonard M Thomas; Tara L Chapman; Astrid P Heikema; Anthony P West; Pamela J Bjorkman
Journal:  BMC Struct Biol       Date:  2002-10-11
View more
  20 in total

Review 1.  KIR and HLA under pressure: evidences of coevolution across worldwide populations.

Authors:  Danillo G Augusto; Maria Luiza Petzl-Erler
Journal:  Hum Genet       Date:  2015-06-23       Impact factor: 4.132

2.  Pemphigus is associated with KIR3DL2 expression levels and provides evidence that KIR3DL2 may bind HLA-A3 and A11 in vivo.

Authors:  Danillo G Augusto; Geraldine M O'Connor; Sara C Lobo-Alves; Sara Bass; Maureen P Martin; Mary Carrington; Daniel W McVicar; Maria Luiza Petzl-Erler
Journal:  Eur J Immunol       Date:  2015-05-06       Impact factor: 5.532

Review 3.  Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.

Authors:  Susanne Juhl Pedersen; Walter P Maksymowych
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

4.  An HLA-B27 Homodimer Specific Antibody Recognizes a Discontinuous Mixed-Disulfide Epitope as Identified by Affinity-Mass Spectrometry.

Authors:  Marius-Ionuţ Iuraşcu; Osiris Marroquin Belaunzanar; Claudia Cozma; Ulf Petrausch; Christoph Renner; Michael Przybylski
Journal:  J Am Soc Mass Spectrom       Date:  2016-04-11       Impact factor: 3.109

Review 5.  The Pathogenesis of Ankylosing Spondylitis: an Update.

Authors:  Susanne Juhl Pedersen; Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2019-11-11       Impact factor: 4.592

Review 6.  HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications.

Authors:  Robert Busch; Simon Kollnberger; Elizabeth D Mellins
Journal:  Nat Rev Rheumatol       Date:  2019-06       Impact factor: 20.543

7.  New perspectives on the ligands and function of the killer cell immunoglobulin-like receptor KIR3DL2 in health and disease.

Authors:  Jacqueline Shaw; Simon Kollnberger
Journal:  Front Immunol       Date:  2012-11-16       Impact factor: 7.561

Review 8.  Aberrant antigen processing and presentation: Key pathogenic factors leading to immune activation in Ankylosing spondylitis.

Authors:  Akihiro Nakamura; Shaghayegh Foroozan Boroojeni; Nigil Haroon
Journal:  Semin Immunopathol       Date:  2021-02-02       Impact factor: 11.759

Review 9.  The danger model approach to the pathogenesis of the rheumatic diseases.

Authors:  César Pacheco-Tena; Susana Aideé González-Chávez
Journal:  J Immunol Res       Date:  2015-04-20       Impact factor: 4.818

10.  KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis.

Authors:  Isabel Wong-Baeza; Anna Ridley; Jackie Shaw; Hiroko Hatano; Oliwia Rysnik; Kirsty McHugh; Christopher Piper; Simon Brackenbridge; Ricardo Fernandes; Anthoni Chan; Paul Bowness; Simon Kollnberger
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.